Akman A, Irkeç M, Orhan M
Department of Ophthalmology, School of Medicine Başkent University, Ankara, Turkey.
Eye (Lond). 1998;12 ( Pt 2):291-5. doi: 10.1038/eye.1998.67.
We compared tear leukotriene B4 (LTB4) and leukotriene C4 (LTC4) levels of vernal keratoconjunctivitis (VKC) patients with those of age-matched controls and evaluated the effects of disodium cromoglycate (DCG) 2%, lodoxamide 0.1% and fluorometholone 0.1% on the tear LTB4 and LTC4 levels of the VKC patients.
Thirty VKC patients were divided into three groups and their tear LTB4 and LTC4 levels measured with an enzyme-linked immunoassay technique before and after treatment with either lodoxamide 0.1%, DCG 2% or fluorometholone 0.1%. The results were compared with the tear LTB4 and LTC4 levels of 10 healthy control subjects. During this trial period, clinical scores for signs and symptoms of VKC were also evaluated.
In the VKC patients median tear LTB4 and LTC4 levels were 349.0 pg/ml (range 213.3-707.7 pg/ml) and 225.2 pg/ml (range 196.1-241.1 pg/ml) respectively--significantly higher than the control group (p = 0.0065 for LTB4 and p = 0.0003 for LTC4). After treatment, LTB4 levels decreased significantly in all treatment groups when compared with baseline (for the lodoxamide group, p = 0.01; for the DCG group, p = 0.008; for the fluorometholone group, p = 0.045). LTC4 levels were also significantly reduced after treatment in all three treatment groups (for the lodoxamide group, p = 0.0209; for the DCG group, p = 0.0284; for the fluorometholone group, p = 0.0109).
Tear LTB4 and LTC4 levels are significantly higher in VKC patients than controls, which points to a possible role of lipoxygenase pathway products in the pathophysiology of ocular allergic disorders. Lodoxamide 0.1%, DCG 2% and fluorometholone 0.1% were all effective in reducing LTB4 and LTC4 levels in VKC.
我们比较了春季角结膜炎（VKC）患者与年龄匹配的对照组的泪液白三烯B4（LTB4）和白三烯C4（LTC4）水平，并评估了2%色甘酸钠（DCG）、0.1%洛度沙胺和0.1%氟米龙对VKC患者泪液LTB4和LTC4水平的影响。
30例VKC患者分为三组，在使用0.1%洛度沙胺、2% DCG或0.1%氟米龙治疗前后，采用酶联免疫分析技术测量他们的泪液LTB4和LTC4水平。将结果与10名健康对照者的泪液LTB4和LTC4水平进行比较。在此试验期间，还评估了VKC体征和症状的临床评分。
VKC患者泪液LTB4和LTC4的中位数水平分别为349.0 pg/ml（范围213.3 - 707.7 pg/ml）和225.2 pg/ml（范围196.1 - 241.1 pg/ml），显著高于对照组（LTB4为p = 0.0065，LTC4为p = 0.0003）。治疗后，与基线相比，所有治疗组的LTB4水平均显著降低（洛度沙胺组，p = 0.01；DCG组，p = 0.008；氟米龙组，p = 0.045）。所有三个治疗组治疗后LTC4水平也显著降低（洛度沙胺组，p = 0.0209；DCG组，p = 0.0284；氟米龙组，p = 0.0109）。
VKC患者泪液LTB4和LTC4水平显著高于对照组，这表明脂氧合酶途径产物在眼部过敏性疾病的病理生理学中可能起作用。0.1%洛度沙胺、2% DCG和0.1%氟米龙均可有效降低VKC患者的LTB4和LTC4水平。
